A Study of Guselkumab in Participants With Systemic Sclerosis

Clinical trial NCT04683029 · COMPLETED

Trial details

NCT number: NCT04683029
Sponsor: Janssen Pharmaceutical K.K.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Scleroderma, Systemic

Start date: 2021-02-24
Primary completion: 2023-05-17
Enrollment: 56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.